Sarosh Nagar joins Ethics Talk to discuss his article, coauthored with Drs Leah Z. Rand and Aaron S. Kesselheim: “What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?”
Dr Nisha M. Patel joins Ethics Talk to discuss her article, coauthored with Drs Jesse M. Ehrenfeld and Brian J. Miller: “What Should ‘Shopping’ Look Like in Actual Practice?”
Clinical needs of patients with disabilities are seen with the “medical gaze,” a depersonalized lens of evidence-based medicine and of presumed objectivity.
AMA J Ethics. 2023;25(1):E85-87. doi:
10.1001/amajethics.2023.85.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
AMA J Ethics. 2022;24(11):E1069-1074. doi:
10.1001/amajethics.2022.1069.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.